microRNAs as biomarkers of ovarian cancer

References

• Ozols RF. Update on the management of ovarian cancer. Cancer J. 2002;8(Suppl 1):S22–30.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Memarzadeh S, Berek JS. Advances in the management of epithelial ovarian cancer. J Reprod Med. 2001;46(7):621–629. discussion 629-30.
   PubMed Web of Science ®Google Scholar
• Guppy AE, Nathan PD, Rustin GJ. Epithelial ovarian cancer: a review of current management. Clin Oncol (R Coll Radiol). 2005;17(6):399–411.
   PubMed Web of Science ®Google Scholar
• Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61(3):183–203.
   PubMed Web of Science ®Google Scholar
• Balch C, Huang TH, Brown R, et al. The epigenetics of ovarian cancer drug resistance and resensitization. Am J Obstet Gynecol. 2004;191(5):1552–1572.
   PubMed Web of Science ®Google Scholar
• Scaletta G, Plotti F, Luvero D, et al. The role of novel biomarker HE4 in the diagnosis, prognosis and follow-up of ovarian cancer: a systematic review. Expert Rev Anticancer Ther. 2017;17(9):827–839.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tian XJ, Xing J. Signal transduction Pathways of EMT induced by TGF-beta, SHH, and WNT and their crosstalks. J Clin Med. 2016;5(4): 41.
   Web of Science ®Google Scholar
• Derynck R, Muthusamy BP, Saeteurn KY. Signaling pathway cooperation in TGF-β-induced epithelial–mesenchymal transition. Curr Opin Cell Biol. 2014;31:56–66.
   PubMed Web of Science ®Google Scholar
• Shan Y, Zhang L, Bao Y, et al. Epithelial-mesenchymal transition, a novel target of sulforaphane via COX-2/MMP2, 9/Snail, ZEB1 and miR-200c/ZEB1 pathways in human bladder cancer cells. J Nutr Biochem. 2013;24(6):1062–1069.
   PubMed Web of Science ®Google Scholar
• Marcus AI, Zhou J, O’Brate A, et al. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res. 2005;65(9):3883–3893.
   PubMed Web of Science ®Google Scholar
• Kostova I. Platinum complexes as anticancer agents. Recent Pat Anticancer Drug Discov. 2006;1(1):1–22.
   PubMed Web of Science ®Google Scholar
• Ozes AR, Miller DF, Ozes ON, et al. NF-kappaB-HOTAIR axis links DNA damage response, chemoresistance and cellular senescence in ovarian cancer. Oncogene. 2016;35(41):5350–5361.
   PubMed Web of Science ®Google Scholar
• Choi YH, Yu AM. ABC transporters in multidrug resistance and pharmacokinetics, and strategies for drug development. Curr Pharm Des. 2014;20(5):793–807.
   PubMed Web of Science ®Google Scholar
• Rich JN, Bao S. Chemotherapy and cancer stem cells. Cell Stem Cell. 2007;1(4):353–355.
   PubMed Web of Science ®Google Scholar
• Liao J, Qian F, Tchabo N, et al. Ovarian cancer spheroid cells with stem cell-like properties contribute to tumor generation, metastasis and chemotherapy resistance through hypoxia-resistant metabolism. PLoS One. 2014;9(1):e84941.
   PubMed Web of Science ®Google Scholar
• Hu L, McArthur C, Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010;102(8):1276–1283.
   PubMed Web of Science ®Google Scholar
• Foster R, Buckanovich RJ, Rueda BR. Ovarian cancer stem cells: working towards the root of stemness. Cancer Lett. 2013;338(1):147–157.
   PubMed Web of Science ®Google Scholar
• Motohara T, Katabuchi H. Ovarian cancer stemness: biological and clinical implications for metastasis and chemotherapy resistance. Cancers (Basel). 2019;11(7):907.
   PubMed Web of Science ®Google Scholar
• Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis. Br J Cancer. 2006;94(6):776–780.
   PubMed Web of Science ®Google Scholar
• Das A, Ganesh K, Khanna S, et al. Engulfment of apoptotic cells by macrophages: a role of microRNA-21 in the resolution of wound inflammation. J Immunol. 2014;192(3):1120–1129.
   PubMed Web of Science ®Google Scholar
• Mirzaei H. Stroke in women: risk factors and clinical biomarkers. J Cell Biochem. 2017;118(12):4191–4202.
   PubMed Web of Science ®Google Scholar
• Salarinia R, Sahebkar A, Peyvandi M, et al. Epi-drugs and epi-miRs: moving beyond current cancer therapies. Curr Cancer Drug Targets. 2016;16(9):773–788.
   PubMed Web of Science ®Google Scholar
• Rashidi B, Hoseini Z, Sahebkar A, et al. Anti-atherosclerotic effects of vitamins D and E in suppression of atherogenesis. J Cell Physiol. 2017;232(11):2968–2976.
   PubMed Web of Science ®Google Scholar
• Mirzaei H, GA F, Avan A, et al. Cytokines and microRNA in coronary artery disease. Adv Clin Chem. 2017;82:47–70.
   PubMed Web of Science ®Google Scholar
• Saeedi Borujeni MJ, Esfandiary E, Taheripak G, et al. Molecular aspects of diabetes mellitus: resistin, microRNA, and exosome. J Cell Biochem. 2018;119(2):1257–1272.
   PubMed Web of Science ®Google Scholar
• Mirzaei H, Yazdi F, Salehi R, et al. SiRNA and epigenetic aberrations in ovarian cancer. J Cancer Res Ther. 2016;12(2):498–508.
   PubMed Web of Science ®Google Scholar
• Fathullahzadeh S, Mirzaei H, Honardoost MA, et al. Circulating microRNA-192 as a diagnostic biomarker in human chronic lymphocytic leukemia. Cancer Gene Ther. 2016;23(10):327–332.
   PubMed Web of Science ®Google Scholar
• Simonian M, Mosallayi M, Mirzaei H. Circulating miR-21 as novel biomarker in gastric cancer: diagnostic and prognostic biomarker. J Cancer Res Ther. 2018;14(2):475.
   PubMed Web of Science ®Google Scholar
• Vafadar A, Shabaninejad Z, Movahedpour A, et al. Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells. Cell Biosci. 2020;10(1):32.
   PubMed Web of Science ®Google Scholar
• Mirzaei H, Fathullahzadeh S, Khanmohammadi R, et al. State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. J Cell Physiol. 2018;233(2):888–900.
   PubMed Web of Science ®Google Scholar
• Mohammadi M, Goodarzi M, Jaafari MR, et al. Circulating microRNA: a new candidate for diagnostic biomarker in neuroblastoma. Cancer Gene Ther. 2016;23(11):371–372.
   PubMed Web of Science ®Google Scholar
• Srivastava SK, Ahmad A, Zubair H, et al. MicroRNAs in gynecological cancers: small molecules with big implications. Cancer Lett. 2017;407(undefined):123–138.
   PubMedGoogle Scholar
• MV I, CM C. Commentary on microRNA fingerprint in human epithelial ovarian cancer. Cancer Res. 2016;76(21):6143–6145.
   PubMed Web of Science ®Google Scholar
• Yang H, Kong W, He L, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68(2):425–433.
   PubMed Web of Science ®Google Scholar
• Koutsaki M, Spandidos DA, Zaravinos A. Epithelial-mesenchymal transition-associated miRNAs in ovarian carcinoma, with highlight on the miR-200 family: prognostic value and prospective role in ovarian cancer therapeutics. Cancer Lett. 2014;351(2):173–181.
   PubMed Web of Science ®Google Scholar
• Xu CX, Xu M, Tan L, et al. MicroRNA miR-214 regulates ovarian cancer cell stemness by targeting p53/Nanog. J Biol Chem. 2012;287(42):34970–34978.
   PubMed Web of Science ®Google Scholar
• Cheng L, Sharples RA, Scicluna BJ, et al. Exosomes provide a protective and enriched source of miRNA for biomarker profiling compared to intracellular and cell-free blood. J Extracell Vesicles. 2014;3. DOI:10.3402/jev.v3.24384.
   PubMedGoogle Scholar
• Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13–21.
   PubMed Web of Science ®Google Scholar
• Gholamin S, Mirzaei H, Razavi SM, et al. GD2-targeted immunotherapy and potential value of circulating microRNAs in neuroblastoma. J Cell Physiol. 2018;233(2):866–879.
   PubMed Web of Science ®Google Scholar
• Gholamin S, Pasdar A, Sadegh Khorrami M, et al. The potential for circulating microRNAs in the diagnosis of myocardial infarction: a novel approach to disease diagnosis and treatment. Curr Pharm Des. 2016;22(3):397–403.
   PubMed Web of Science ®Google Scholar
• Feng W, Dean DC, Hornicek FJ, et al. Exosomes promote pre-metastatic niche formation in ovarian cancer. Mol Cancer. 2019;18(1):124.
   PubMed Web of Science ®Google Scholar
• Becker A, Thakur BK, Weiss JM, et al. Extracellular vesicles in cancer: cell-to-cell mediators of metastasis. Cancer Cell. 2016;30(6):836–848.
   PubMed Web of Science ®Google Scholar
• Lagos-Quintana M, Rauhut R, Lendeckel W, et al. Identification of novel genes coding for small expressed RNAs. Science. 2001;294(5543):853–858.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–297.
   PubMed Web of Science ®Google Scholar
• Lee Y, Ahn C, Han J, et al. The nuclear RNase III Drosha initiates microRNA processing. Nature. 2003;425(6956):415–419.
   PubMed Web of Science ®Google Scholar
• Kim YK, Kim VN. Processing of intronic microRNAs. Embo J. 2007;26(3):775–783.
   PubMed Web of Science ®Google Scholar
• Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509–524.
   PubMed Web of Science ®Google Scholar
• Piletič K, Kunej T. MicroRNA epigenetic signatures in human disease. Arch Toxicol. 2016;90(10):2405–2419.
   PubMed Web of Science ®Google Scholar
• Pratt AJ, MacRae IJ. The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem. 2009;284(27):17897–17901.
   PubMed Web of Science ®Google Scholar
• Rabieian R, Boshtam M, Zareei M, et al. Plasminogen activator inhibitor type-1 as a regulator of fibrosis. J Cell Biochem. 2018;119(1):17–27.
   PubMed Web of Science ®Google Scholar
• Banikazemi Z, Haji H, Mohammadi M, et al. Diet and cancer prevention: dietary compounds, dietary microRNAs, and dietary exosomes. J Cell Biochem. 2018;119(1):185–196.
   PubMed Web of Science ®Google Scholar
• Tang W, Wan S, Yang Z, et al. Tumor origin detection with tissue-specific miRNA and DNA methylation markers. Bioinformatics. 2018;34(3):398–406.
   PubMed Web of Science ®Google Scholar
• Pu Q, Huang Y, Lu Y, et al. Tissue-specific and plasma microRNA profiles could be promising biomarkers of histological classification and TNM stage in non-small cell lung cancer. Thorac Cancer. 2016;7(3):348–354.
   PubMed Web of Science ®Google Scholar
• Tan G, Cao X, Dai Q, et al. A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Oncotarget. 2015;6(11):8676–8686.
   PubMedGoogle Scholar
• Dey SK, Wyman SK, Parkin RK, et al. Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS ONE. 2009;4(4):e5311.
   PubMed Web of Science ®Google Scholar
• Nakano H, Yamada Y, Miyazawa T, et al. Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol. 2013;42(6):1875–1882.
   PubMed Web of Science ®Google Scholar
• Hu L, Kolibaba H, Zhang S, et al. MicroRNA-204-5p inhibits ovarian cancer cell proliferation by down-regulating USP47. Cell Transplant. 2019;undefined(undefined):963689719877372.
   Google Scholar
• Huang Z, Li Q, Luo K, et al. miR-340-FHL2 axis inhibits cell growth and metastasis in ovarian cancer. Cell Death Dis. 2019;10(5):372.
   PubMedGoogle Scholar
• Guo LM, Pu Y, Han Z, et al. MicroRNA-9 inhibits ovarian cancer cell growth through regulation of NF-kappaB1. FEBS J. 2009;276(19):5537–5546.
   PubMed Web of Science ®Google Scholar
• Jin M, Yang Z, Ye W, et al. MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1. PLoS One. 2014;9(8):e103965.
   PubMed Web of Science ®Google Scholar
• Liu G, Sun Y, Ji P, et al. MiR-506 suppresses proliferation and induces senescence by directly targeting the CDK4/6-FOXM1 axis in ovarian cancer. J Pathol. 2014;233(3):308–318.
   PubMed Web of Science ®Google Scholar
• Flavin R, Smyth P, Barrett C, et al. miR-29b expression is associated with disease-free survival in patients with ovarian serous carcinoma. Int J Gynecol Cancer. 2009;19(4):641–647.
   PubMed Web of Science ®Google Scholar
• Yan J, Jiang JY, XN M, et al. MiR-23b targets cyclin G1 and suppresses ovarian cancer tumorigenesis and progression. J Exp Clin Cancer Res. 2016;35(undefined):31.
   PubMedGoogle Scholar
• Zhang Z, Zhang L, Wang B, et al. MiR-337-3p suppresses proliferation of epithelial ovarian cancer by targeting PIK3CA and PIK3CB. Cancer Lett. 2020;469(undefined):54–67.
   PubMedGoogle Scholar
• Chen S, Chen X, Xiu YL, et al. MicroRNA-490-3P targets CDK1 and inhibits ovarian epithelial carcinoma tumorigenesis and progression. Cancer Lett. 2015;362(1):122–130.
   PubMed Web of Science ®Google Scholar
• Majem B, Parrilla A, Jiménez C, et al. MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. Oncogene. 2019;38(32):6035–6050.
   PubMed Web of Science ®Google Scholar
• Jeong JY, Kang H, Kim TH, et al. MicroRNA-136 inhibits cancer stem cell activity and enhances the anti-tumor effect of paclitaxel against chemoresistant ovarian cancer cells by targeting Notch3. Cancer Lett. 2017;386(undefined):168–178.
   PubMedGoogle Scholar
• Yang D, Sun Y, Hu L, et al. Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell. 2013;23(2):186–199.
   PubMed Web of Science ®Google Scholar
• Zhao H, Liu S, Wang G, et al. Expression of miR-136 is associated with the primary cisplatin resistance of human epithelial ovarian cancer. Oncol Rep. 2015;33(2):591–598.
   PubMed Web of Science ®Google Scholar
• Dai F, Zhang Y, Chen Y. Involvement of miR-29b signaling in the sensitivity to chemotherapy in patients with ovarian carcinoma. Hum Pathol. 2014;45(6):1285–1293.
   PubMed Web of Science ®Google Scholar
• Tung SL, Huang WC, Hsu FC, et al. miRNA-34c-5p inhibits amphiregulin-induced ovarian cancer stemness and drug resistance via downregulation of the AREG-EGFR-ERK pathway. Oncogenesis. 2017;6(5):e326.
   PubMed Web of Science ®Google Scholar
• Xia Y, Gao Y. MicroRNA-181b promotes ovarian cancer cell growth and invasion by targeting LATS2. Biochem Biophys Res Commun. 2014;447(3):446–451.
   PubMed Web of Science ®Google Scholar
• Yang Z, Wang XL, Bai R, et al. miR-23a promotes IKKα expression but suppresses ST7L expression to contribute to the malignancy of epithelial ovarian cancer cells. Br J Cancer. 2016;115(6):731–740.
   PubMed Web of Science ®Google Scholar
• Nam EJ, Yoon H, Kim SW, et al. MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res. 2008;14(9):2690–2695.
   PubMed Web of Science ®Google Scholar
• Shen W, Song M, Liu J, et al. MiR-26a promotes ovarian cancer proliferation and tumorigenesis. PLoS One. 2014;9(1):e86871.
   PubMed Web of Science ®Google Scholar
• Zhang J, Liu W, Shen F, et al. The activation of microRNA-520h-associated TGF-beta1/c-Myb/Smad7 axis promotes epithelial ovarian cancer progression. Cell Death Dis. 2018;9(9):884.
   PubMedGoogle Scholar
• Chaluvally-Raghavan P, Jeong KJ, Pradeep S, et al. Direct upregulation of STAT3 by microRNA-551b-3p deregulates growth and metastasis of ovarian cancer. Cell Rep. 2016;15(7):1493–1504.
   PubMed Web of Science ®Google Scholar
• Abubaker K, Luwor RB, Escalona R, et al. Targeted disruption of the JAK2/STAT3 pathway in combination with systemic administration of paclitaxel inhibits the priming of ovarian cancer stem cells leading to a reduced tumor burden. Front Oncol. 2014;4:75.
   PubMedGoogle Scholar
• Sun J, Cai X, Yung MM, et al. miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer. Oncogene. 2019;38(4):564–580.
   PubMed Web of Science ®Google Scholar
• Sorrentino A, Liu CG, Addario A, et al. Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol. 2008;111(3):478–486.
   PubMed Web of Science ®Google Scholar
• Cui X, Sun Y, Shen M, et al., Enhanced chemotherapeutic efficacy of paclitaxel nanoparticles co-delivered with microRNA-7 by inhibiting paclitaxel-induced EGFR/ERK pathway activation for ovarian cancer therapy. ACS Appl Mater Interfaces. 2018;10(9): 7821–7831. .
   PubMed Web of Science ®Google Scholar
• Zhang L, Li Z, Gai F, et al. MicroRNA-137 suppresses tumor growth in epithelial ovarian cancer in vitro and in vivo. Mol Med Rep. 2015;12(2):3107–3114.
   PubMed Web of Science ®Google Scholar
• Li X, Chen W, Zeng W, et al. microRNA-137 promotes apoptosis in ovarian cancer cells via the regulation of XIAP. Br J Cancer. 2017;116(1):66–76.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang X, Tang W, et al. miR-130a upregulates mTOR pathway by targeting TSC1 and is transactivated by NF-κB in high-grade serous ovarian carcinoma. Cell Death Differ. 2017;24(12):2089–2100.
   PubMed Web of Science ®Google Scholar
• V O, J J, P O, et al., DNA methylation of miR-7 is a mechanism involved in platinum response through overexpression in cancer cells. Theranostics. 2017;7(17): 4118–4134.
   PubMed Web of Science ®Google Scholar
• Wu J, Sun Y, Zhang PY, et al. The Fra-1-miR-134-SDS22 feedback loop amplifies ERK/JNK signaling and reduces chemosensitivity in ovarian cancer cells. Cell Death Dis. 2016;7(9):e2384.
   PubMedGoogle Scholar
• Kanlikilicer P, Bayraktar R, Denizli M, et al. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018;38(undefined):100–112.
   PubMedGoogle Scholar
• Wang Y, Bao W, Liu Y, et al. miR-98-5p contributes to cisplatin resistance in epithelial ovarian cancer by suppressing miR-152 biogenesis via targeting Dicer1. Cell Death Dis. 2018;9(5):447.
   PubMedGoogle Scholar
• Heerboth S, Housman G, Leary M, et al. EMT and tumor metastasis. Clin Transl Med. 2015;4:6.
   PubMed Web of Science ®Google Scholar
• Wang L, Mezencev R, Švajdler M, et al. Ectopic over-expression of miR-429 induces mesenchymal-to-epithelial transition (MET) and increased drug sensitivity in metastasizing ovarian cancer cells. Gynecol Oncol. 2014;134(1):96–103.
   PubMed Web of Science ®Google Scholar
• Yew KH, Crow J, Hirst J, et al. Epimorphin-induced MET sensitizes ovarian cancer cells to platinum. PLoS One. 2013;8(9):e72637.
   PubMed Web of Science ®Google Scholar
• Mak CS, Yung MM, Hui LM, et al. MicroRNA-141 enhances anoikis resistance in metastatic progression of ovarian cancer through targeting KLF12/Sp1/survivin axis. Mol Cancer. 2017;16(1):11.
   PubMedGoogle Scholar
• Lin KT, Yeh YM, Chuang CM, et al. Glucocorticoids mediate induction of microRNA-708 to suppress ovarian cancer metastasis through targeting Rap1B. Nat Commun. 2015;6:5917.
   PubMed Web of Science ®Google Scholar
• Yeh YM, Chuang CM, Chao KC, et al. MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1alpha. Int J Cancer. 2013;133(4):867–878.
   PubMed Web of Science ®Google Scholar
• Joshi HP, Subramanian IV, Schnettler EK, et al. Dynamin 2 along with microRNA-199a reciprocally regulate hypoxia-inducible factors and ovarian cancer metastasis. Proc Natl Acad Sci USA. 2014;111(14):5331–5336.
   PubMed Web of Science ®Google Scholar
• Wen Z, Zhao S, Liu S, et al. MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1. Mol Med Rep. 2015;12(3):3775–3780.
   PubMed Web of Science ®Google Scholar
• Xing F, Wang S, Zhou J. The expression of microRNA-598 inhibits ovarian cancer cell proliferation and metastasis by targeting URI. Mol Ther Oncolytics. 2019;12(undefined):9–15.
   PubMedGoogle Scholar
• Srivastava AK, Banerjee A, Cui T, et al. Inhibition of miR-328-3p impairs cancer stem cell function and prevents metastasis in ovarian cancer. Cancer Res. 2019;79(9):2314–2326.
   PubMed Web of Science ®Google Scholar
• Qin W, Ren Q, Liu T, et al. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1. FEBS Lett. 2013;587(9):1434–1439.
   PubMed Web of Science ®Google Scholar
• Zhao G, Guo Y, Chen Z, et al. miR-203 functions as a tumor suppressor by inhibiting epithelial to mesenchymal transition in ovarian cancer. J Cancer Sci Ther. 2015;7(2):34–43.
   PubMedGoogle Scholar
• Wang B, Li X, Zhao G, et al. miR-203 inhibits ovarian tumor metastasis by targeting BIRC5 and attenuating the TGFβ pathway. J Exp Clin Cancer Res. 2018;37(1):235.
   PubMedGoogle Scholar
• Zhou X, Hu Y, Dai L, et al. MicroRNA-7 inhibits tumor metastasis and reverses epithelial-mesenchymal transition through AKT/ERK1/2 inactivation by targeting EGFR in epithelial ovarian cancer. PLoS One. 2014;9(5):e96718.
   PubMed Web of Science ®Google Scholar
• Dong P, Xiong Y, Watari H, et al. MiR-137 and miR-34a directly target Snail and inhibit EMT, invasion and sphere-forming ability of ovarian cancer cells. J Exp Clin Cancer Res. 2016;35(1):132.
   PubMedGoogle Scholar
• Muys BR, Sousa JF, Plaça JR, et al. miR-450a acts as a tumor suppressor in ovarian cancer by regulating energy metabolism. Cancer Res. 2019;79(13):3294–3305.
   PubMed Web of Science ®Google Scholar
• Zhao L, Wang W, Xu L, et al. Integrative network biology analysis identifies miR-508-3p as the determinant for the mesenchymal identity and a strong prognostic biomarker of ovarian cancer. Oncogene. 2019;38(13):2305–2319.
   PubMed Web of Science ®Google Scholar
• Vang S, Wu HT, Fischer A, et al. Identification of ovarian cancer metastatic miRNAs. PLoS One. 2013;8(3):e58226.
   PubMed Web of Science ®Google Scholar
• Yong W, Yu D, Jun Z, et al. Long noncoding RNA NEAT1, regulated by LIN28B, promotes cell proliferation and migration through sponging miR-506 in high-grade serous ovarian cancer. Cell Death Dis. 2018;9(9):861.
   PubMed Web of Science ®Google Scholar
• Liu H, Pan Y, Han X, et al. MicroRNA-216a promotes the metastasis and epithelial-mesenchymal transition of ovarian cancer by suppressing the PTEN/AKT pathway. Onco Targets Ther. 2017;10:2701–2709.
   PubMed Web of Science ®Google Scholar
• Salem M, O’Brien JA, Bernaudo S, et al. miR-590-3p promotes ovarian cancer growth and metastasis via a novel FOXA2-versican pathway. Cancer Res. 2018;78(15):4175–4190.
   PubMed Web of Science ®Google Scholar
• Rosano L, Cianfrocca R, Spinella F, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin a receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17(8):2350–2360.
   PubMed Web of Science ®Google Scholar
• Lili LN, Huang AD, Zhang M, et al. Time-course analysis of microRNA-induced mesenchymal-to-epithelial transition underscores the complexity of the underlying molecular processes. Cancer Lett. 2018;428(undefined):184–191.
   PubMedGoogle Scholar
• Zhang M, Jabbari N, Satpathy M, et al. Sequence diverse miRNAs converge to induce mesenchymal-to-epithelial transition in ovarian cancer cells through direct and indirect regulatory controls. Cancer Lett. 2019;459(undefined):168–175.
   PubMedGoogle Scholar
• Chen J, Wang L, Matyunina LV, et al. Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gynecol Oncol. 2011;121(1):200–205.
   PubMed Web of Science ®Google Scholar
• Luo X, Dong Z, Chen Y, et al. Enrichment of ovarian cancer stem-like cells is associated with epithelial to mesenchymal transition through an miRNA-activated AKT pathway. Cell Prolif. 2013;46(4):436–446.
   PubMed Web of Science ®Google Scholar
• Chen D, Zhang Y, Wang J, et al. MicroRNA-200c overexpression inhibits tumorigenicity and metastasis of CD117+CD44+ ovarian cancer stem cells by regulating epithelial-mesenchymal transition. J Ovarian Res. 2013;6(1):50.
   PubMed Web of Science ®Google Scholar
• Wu Q, Guo R, Lin M, et al. MicroRNA-200a inhibits CD133/1+ ovarian cancer stem cells migration and invasion by targeting E-cadherin repressor ZEB2. Gynecol Oncol. 2011;122(1):149–154.
   PubMed Web of Science ®Google Scholar
• Tang MK, Wong AS. Exosomes: emerging biomarkers and targets for ovarian cancer. Cancer Lett. 2015;367(1):26–33.
   PubMed Web of Science ®Google Scholar
• Li X, Wang X. The emerging roles and therapeutic potential of exosomes in epithelial ovarian cancer. Mol Cancer. 2017;16(1):92.
   PubMedGoogle Scholar
• Dorayappan KDP, Wallbillich JJ, Cohn DE, et al. The biological significance and clinical applications of exosomes in ovarian cancer. Gynecol Oncol. 2016;142(1):199–205.
   PubMed Web of Science ®Google Scholar
• Alharbi M, Zuniga F, Elfeky O, et al. The potential role of miRNAs and exosomes in chemotherapy in ovarian cancer. Endocr Relat Cancer. 2018;25(12):R663–R685.
   PubMed Web of Science ®Google Scholar
• Nakamura K, Sawada K, Kobayashi M, et al. Role of the exosome in ovarian cancer progression and its potential as a therapeutic target. Cancers (Basel). 2019;11(8):1147.
   Web of Science ®Google Scholar
• Vella LJ. The emerging role of exosomes in epithelial-mesenchymal-transition in cancer. Front Oncol. 2014;4:361.
   PubMedGoogle Scholar
• Szajnik M, Derbis M, Lach M, et al. Exosomes in plasma of patients with ovarian carcinoma: potential biomarkers of tumor progression and response to therapy. Gynecol Obstet (Sunnyvale). 2013;(Suppl 4):3.
   PubMedGoogle Scholar
• Nakamura K, Sawada K, Yoshimura A, et al. Clinical relevance of circulating cell-free microRNAs in ovarian cancer. Mol Cancer. 2016;15(1):48.
   PubMed Web of Science ®Google Scholar
• Pan C, Stevic I, Müller V, et al. Exosomal microRNAs as tumor markers in epithelial ovarian cancer. Mol Oncol. 2018;12(11):1935–1948.
   PubMed Web of Science ®Google Scholar
• Matsumura T, Sugimachi K, Iinuma H, et al. Exosomal microRNA in serum is a novel biomarker of recurrence in human colorectal cancer. Br J Cancer. 2015;113(2):275–281.
   PubMed Web of Science ®Google Scholar
• Kobayashi M, Salomon C, Tapia J, et al. Ovarian cancer cell invasiveness is associated with discordant exosomal sequestration of Let-7 miRNA and miR-200. J Transl Med. 2014;12(1):4.
   PubMedGoogle Scholar
• Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014;30(1):255–289.
   PubMed Web of Science ®Google Scholar
• Yoshimura A, Sawada K, Nakamura K, et al. Exosomal miR-99a-5p is elevated in sera of ovarian cancer patients and promotes cancer cell invasion by increasing fibronectin and vitronectin expression in neighboring peritoneal mesothelial cells. BMC Cancer. 2018;18(1):1065.
   PubMedGoogle Scholar
• Chen X, Zhou J, Li X, et al. Exosomes derived from hypoxic epithelial ovarian cancer cells deliver microRNAs to macrophages and elicit a tumor-promoted phenotype. Cancer Lett. 2018;435:80–91.
   PubMed Web of Science ®Google Scholar
• Chen X, Ying X, Wang X, et al. Exosomes derived from hypoxic epithelial ovarian cancer deliver microRNA-940 to induce macrophage M2 polarization. Oncol Rep. 2017;38(1):522–528.
   PubMed Web of Science ®Google Scholar
• Ying X, Wu Q, Wu X, et al. Epithelial ovarian cancer-secreted exosomal miR-222-3p induces polarization of tumor-associated macrophages. Oncotarget. 2016;7(28):43076–43087.
   PubMedGoogle Scholar
• Zhou J, Li X, Wu X, et al. Exosomes released from tumor-associated macrophages transfer miRNAs that induce a Treg/Th17 cell imbalance in epithelial ovarian cancer. Cancer Immunol Res. 2018;6(12):1578–1592.
   PubMed Web of Science ®Google Scholar
• Hu Y, Li D, Wu A, et al. TWEAK-stimulated macrophages inhibit metastasis of epithelial ovarian cancer via exosomal shuttling of microRNA. Cancer Lett. 2017;393:60–67.
   PubMed Web of Science ®Google Scholar
• Kanlikilicer P, Rashed MH, Bayraktar R, et al. Ubiquitous release of exosomal tumor suppressor miR-6126 from ovarian cancer cells. Cancer Res. 2016;76(24):7194–7207.
   PubMed Web of Science ®Google Scholar
• He L, Zhu W, Chen Q, et al. Ovarian cancer cell-secreted exosomal miR-205 promotes metastasis by inducing angiogenesis. Theranostics. 2019;9(26):8206–8220.
   PubMed Web of Science ®Google Scholar
• Au Yeung CL, Co NN, Tsuruga T, et al. Exosomal transfer of stroma-derived miR21 confers paclitaxel resistance in ovarian cancer cells through targeting APAF1. Nat Commun. 2016;7(1):11150.
   PubMed Web of Science ®Google Scholar
• Reid BM, Permuth JB, Chen YA, et al. Integration of population-level genotype data with functional annotation reveals over-representation of long noncoding RNAs at ovarian cancer susceptibility loci. Cancer Epidemiol Biomarkers Prev. 2017;26(1):116–125.
   PubMed Web of Science ®Google Scholar
• Tripathi MK, Doxtater K, Keramatnia F, et al. Role of lncRNAs in ovarian cancer: defining new biomarkers for therapeutic purposes. Drug Discov Today. 2018;23(9):1635–1643.
   PubMed Web of Science ®Google Scholar
• Shabaninejad Z, Vafadar A, Movahedpour A, et al. Circular RNAs in cancer: new insights into functions and implications in ovarian cancer. J Ovarian Res. 2019;12(1):84.
   PubMed Web of Science ®Google Scholar
• Ma Y, Lu Y, Lu B. MicroRNA and long non-coding RNA in ovarian carcinoma: translational insights and potential clinical applications. Cancer Invest. 2016;34(9):465–476.
   PubMed Web of Science ®Google Scholar
• Meryet-Figuiere M, Lambert B, Gauduchon P, et al. An overview of long non-coding RNAs in ovarian cancers. Oncotarget. 2016;7(28):44719–44734.
   PubMed Web of Science ®Google Scholar
• Chen S, Wu DD, Sang XB, et al. The lncRNA HULC functions as an oncogene by targeting ATG7 and ITGB1 in epithelial ovarian carcinoma. Cell Death Dis. 2017;8(10):e3118.
   PubMedGoogle Scholar
• Shang A, Wang W, Gu C, et al. Long non-coding RNA HOTTIP enhances IL-6 expression to potentiate immune escape of ovarian cancer cells by upregulating the expression of PD-L1 in neutrophils. J Exp Clin Cancer Res. 2019;38(1):411.
   PubMed Web of Science ®Google Scholar
• Wu DD, Chen X, Sun KX, et al. Role of the lncRNA ABHD11-AS in the tumorigenesis and progression of epithelial ovarian cancer through targeted regulation of RhoC. Mol Cancer. 2017;16(1):138.
   PubMedGoogle Scholar
• Wang H, Fang L, Jiang J, et al. The cisplatin-induced lncRNA PANDAR dictates the chemoresistance of ovarian cancer via regulating SFRS2-mediated p53 phosphorylation. Cell Death Dis. 2018;9(11):1103.
   PubMedGoogle Scholar
• Ruan Z, Zhao D. Long intergenic noncoding RNA LINC00284 knockdown reduces angiogenesis in ovarian cancer cells via up-regulation of MEST through NF-κB1. Faseb J. 2019;33(11):12047–12059.
   PubMed Web of Science ®Google Scholar
• Rupaimoole R, Lee J, Haemmerle M, et al. Long noncoding RNA ceruloplasmin promotes cancer growth by altering glycolysis. Cell Rep. 2015;13(11):2395–2402.
   PubMed Web of Science ®Google Scholar
• Silva JM, Boczek NJ, Berres MW, et al. LSINCT5 is over expressed in breast and ovarian cancer and affects cellular proliferation. RNA Biol. 2011;8(3):496–505.
   PubMed Web of Science ®Google Scholar
• Horita K, Kurosaki H, Nakatake M, et al. lncRNA UCA1-mediated Cdc42 signaling promotes oncolytic vaccinia virus cell-to-cell spread in ovarian cancer. Mol Ther Oncolytics. 2019;13(undefined):35–48.
   PubMedGoogle Scholar
• Mitra R, Chen X, Greenawalt EJ, et al. Decoding critical long non-coding RNA in ovarian cancer epithelial-to-mesenchymal transition. Nat Commun. 2017;8(1):1604.
   PubMed Web of Science ®Google Scholar
• Long X, Song K, Hu H, et al. Long non-coding RNA GAS5 inhibits DDP-resistance and tumor progression of epithelial ovarian cancer via GAS5-E2F4-PARP1-MAPK axis. J Exp Clin Cancer Res. 2019;38(1):345.
   PubMed Web of Science ®Google Scholar
• Gloss B, Moran-Jones K, Lin V, et al. ZNF300P1 encodes a lincRNA that regulates cell polarity and is epigenetically silenced in type II epithelial ovarian cancer. Mol Cancer. 2014;13(undefined):3.
   PubMedGoogle Scholar
• Yan H, Li H, Li P, et al. Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis. J Exp Clin Cancer Res. 2018;37(1):237.
   PubMedGoogle Scholar
• Liang H, Zhao X, Wang C, et al. Systematic analyses reveal long non-coding RNA (PTAF)-mediated promotion of EMT and invasion-metastasis in serous ovarian cancer. Mol Cancer. 2018;17(1):96.
   PubMedGoogle Scholar
• Yan L, Zhou J, Gao Y, et al. Regulation of tumor cell migration and invasion by the H19/let-7 axis is antagonized by metformin-induced DNA methylation. Oncogene. 2015;34(23):3076–3084.
   PubMed Web of Science ®Google Scholar
• Tao F, Tian X, Ruan S, et al. miR-211 sponges lncRNA MALAT1 to suppress tumor growth and progression through inhibiting PHF19 in ovarian carcinoma. Faseb J. 2018;undefined(undefined):fj201800495RR.
   Google Scholar
• Gokulnath P, de Cristofaro T, Manipur I, et al. Long non-coding RNA MAGI2-AS3 is a new player with a tumor suppressive role in high grade serous ovarian carcinoma. Cancers (Basel). 2019;11(12):undefined.
   Web of Science ®Google Scholar
• Yan H, Li H, Silva MA, et al. LncRNA FLVCR1-AS1 mediates miR-513/YAP1 signaling to promote cell progression, migration, invasion and EMT process in ovarian cancer. J Exp Clin Cancer Res. 2019;38(1):356.
   PubMed Web of Science ®Google Scholar
• Dong S, Wang R, Wang H, et al. HOXD-AS1 promotes the epithelial to mesenchymal transition of ovarian cancer cells by regulating miR-186-5p and PIK3R3. J Exp Clin Cancer Res. 2019;38(1):110.
   PubMedGoogle Scholar
• Liang H, Yu M, Yang R, et al. A PTAL-miR-101-FN1 axis promotes EMT and invasion-metastasis in serous ovarian cancer. Mol Ther Oncolytics. 2020;16:53–62.
   PubMed Web of Science ®Google Scholar
• Liang H, Yu T, Han Y, et al. LncRNA PTAR promotes EMT and invasion-metastasis in serous ovarian cancer by competitively binding miR-101-3p to regulate ZEB1 expression. Mol Cancer. 2018;17(1):119.
   PubMed Web of Science ®Google Scholar
• Lou W, Ding B, Zhong G, et al. Dysregulation of pseudogene/lncRNA-hsa-miR-363-3p-SPOCK2 pathway fuels stage progression of ovarian cancer. Aging (Albany NY). 2019;11(undefined):undefined.
   Google Scholar
• Li Z, Niu H, Qin Q, et al. lncRNA UCA1 mediates resistance to cisplatin by regulating the miR-143/FOSL2-signaling pathway in ovarian cancer. Mol Ther Nucleic Acids. 2019;17(undefined):92–101.
   PubMedGoogle Scholar
• Broutier L, Mastrogiovanni G, Verstegen MM, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424–1435.
   PubMed Web of Science ®Google Scholar
• Kopper O, de Witte CJ, Lohmussaar K, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838–849.
   PubMed Web of Science ®Google Scholar
• Boriachek K, Islam MN, Moller A, et al. Biological functions and current advances in isolation and detection strategies for exosome nanovesicles. Small. 2018;14(6):1702153.
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhou Q, Qiu Q, et al. CircPLEKHM3 acts as a tumor suppressor through regulation of the miR-9/BRCA1/DNAJB6/KLF4/AKT1 axis in ovarian cancer. Mol Cancer. 2019;18(1):144.
   PubMed Web of Science ®Google Scholar
• Miotto E, Saccenti E, Lupini L, et al. Quantification of circulating miRNAs by droplet digital PCR: comparison of EvaGreen- and TaqMan-based chemistries. Cancer Epidemiol Biomarkers Prev. 2014;23(12):2638–2642.
   PubMed Web of Science ®Google Scholar
• Sato H, Soh J, Aoe K, et al. Droplet digital PCR as a novel system for the detection of microRNA‑34b/c methylation in circulating DNA in malignant pleural mesothelioma. Int J Oncol. 2019;54(6):2139–2148.
   PubMed Web of Science ®Google Scholar
• Islam MN, Masud MK, Haque MH, et al. RNA biomarkers: diagnostic and prognostic potentials and recent developments of electrochemical biosensors. Small Methods. 2017;1(7):1700131.
   Web of Science ®Google Scholar
• Islam MN, Masud MK, Nguyen NT, et al. Gold-loaded nanoporous ferric oxide nanocubes for electrocatalytic detection of microRNA at attomolar level. Biosens Bioelectron. 2018;101:275–281.
   PubMed Web of Science ®Google Scholar
• Masud MK, Na J, Younus M, et al. Superparamagnetic nanoarchitectures for disease-specific biomarker detection. Chem Soc Rev. 2019;48(24):5717–5751.
   PubMed Web of Science ®Google Scholar
• Masud MK, Umer M, Hossain MSA, et al. Nanoarchitecture frameworks for electrochemical miRNA detection. Trends Biochem Sci. 2019;44(5):433–452.
   PubMed Web of Science ®Google Scholar
• Koo KM, Carrascosa LG, Shiddiky MJ, et al. Poly(A) extensions of mirnas for amplification-free electrochemical detection on screen-printed gold electrodes. Anal Chem. 2016;88(4):2000–2005.
   PubMed Web of Science ®Google Scholar
• Koo KM, Carrascosa LG, Shiddiky MJ, et al. Amplification-free detection of gene fusions in prostate cancer urinary samples using mRNA-gold affinity interactions. Anal Chem. 2016;88(13):6781–6788.
   PubMed Web of Science ®Google Scholar
• Islam MN, Gopalan V, Haque MH, et al. A PCR-free electrochemical method for messenger RNA detection in cancer tissue samples. Biosens Bioelectron. 2017;98:227–233.
   PubMed Web of Science ®Google Scholar
• Boriachek K, Umer M, Islam MN, et al. An amplification-free electrochemical detection of exosomal miRNA-21 in serum samples. Analyst. 2018;143(7):1662–1669.
   PubMed Web of Science ®Google Scholar